KemPharm, Inc. (KMPH) financial statements (2021 and earlier)

Company profile

Business Address 1180 CELEBRATION BOULEVARD, SUITE 103
CELEBRATION, FL 34747
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments322426851
Cash and cash equivalents318111732
Short-term investments 3315119
Restricted cash and investments  11 
Receivables20252
Prepaid expense00000
Capitalized contract cost1 
Deferred costs0    
Other undisclosed current assets02100
Total current assets:724477454
Noncurrent Assets
Operating lease, right-of-use asset2
Property, plant and equipment12220
Long-term investments and receivables  38 
Long-term investments  38 
Regulated entity, other noncurrent assets    1
Restricted cash and investments01   
Other noncurrent assets11000
Total noncurrent assets:435112
TOTAL ASSETS:1127528556
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:58865
Accounts payable14201
Accrued liabilities11111
Employee-related liabilities01111
Interest and dividends payable02221
Other undisclosed accounts payable and accrued liabilities31221
Debt04403
Other liabilities0000 
Total current liabilities:5121278
Noncurrent Liabilities
Long-term debt and lease obligation7979909120
Long-term debt, excluding current maturities7778899120
Capital lease obligations01  
Operating lease, liability2
Liabilities, other than long-term debt0111 
Other liabilities0111 
Other undisclosed noncurrent liabilities028538
Total noncurrent liabilities:8081989758
Total liabilities:859311010466
Stockholders' equity
Stockholders' equity attributable to parent(74)(67)(58)(19)(10)
Common stock00000
Additional paid in capital17115510710395
Accumulated deficit(246)(221)(165)(121)(105)
Total stockholders' equity:(74)(67)(58)(19)(10)
TOTAL LIABILITIES AND EQUITY:1127528556

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues13    
Cost of revenue
(Cost of Goods and Services Sold)
(10)    
Gross profit:3    
Operating expenses(30)(56)(33)(37)(23)
Other undisclosed operating income7    
Operating loss:(20)(56)(33)(37)(23)
Nonoperating income (expense)(4)(1)(10)21(32)
Interest and debt expense(5)0(6)(5)(3)
Loss from continuing operations before equity method investments, income taxes:(29)(57)(49)(21)(57)
Other undisclosed income (loss) from continuing operations before income taxes5(0)653
Loss from continuing operations before income taxes:(25)(57)(43)(17)(55)
Income tax expense (benefit)0000(0)
Net loss available to common stockholders, diluted:(25)(56)(43)(17)(55)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(25)(56)(43)(17)(55)
Comprehensive loss, net of tax, attributable to parent:(25)(56)(43)(17)(55)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: